Introduction to pemphigus foliaceus

Definition and overview

Pemphigus Foliaceus is a potentially life-threatening autoimmune blistering disease characterized by the presence of antibodies targeting desmogleins, vital components responsible for epidermal cell adhesion. Unlike Pemphigus Vulgaris, where mucosal lesions are predominant, Pemphigus Foliaceus predominantly affects the skin without involving mucosal areas.

The condition is distinguished by the presence of immunoglobulin G (IgG) antibodies specifically directed against desmoglein-1 (Dsg1), located in the granular layer of the epidermis. This attack disrupts the adhesion between skin cells, resulting in the formation of superficial blisters and lesions on the skin's surface.^1,2

Historical background

Pemphigus Foliaceus has been found as a distinct entity from other pemphigus variants due to its specific antibody targets and clinical presentation. Its differentiation from Pemphigus Vulgaris (primarily because of the absence of mucosal involvement) has significantly influenced diagnostic and treatment approaches.

Historically, the understanding and classification of pemphigus diseases have evolved over time, with advancements in immunology and molecular biology contributing to a deeper comprehension of the underlying mechanisms involved in Pemphigus Foliaceus.

Incidence and prevalence

Pemphigus Foliaceus is relatively less common globally compared to Pemphigus Vulgaris. It affects all genders equally, with the typical age of onset ranging between 50 to 60 years. However, cases of Pemphigus Foliaceus have also been reported in children, indicating its potential occurrence across age groups.

Pemphigus has an estimated occurrence rate of approximately 1 in 100,000 people. The condition's onset is attributed to multiple factors, although drug-induced pemphigus stands as the most frequently identified cause. Pemphigus Vulgaris is the most prominent variant among pemphigus diseases, exhibiting an incidence ranging from 0.1 to 0.5 cases per 100,000 individuals.³

Moreover, an endemic form of Pemphigus Foliaceus is prevalent in specific regions such as Tunisia and Brazil, where it is locally termed as "fogo selvagem".⁴ This particular endemic variant often occurs within genetically related family members. Despite its occurrence in clusters, it's important to note that Pemphigus Foliaceus is not contagious and transmission through blood products or body fluids has not been documented.

Causes and risk factors

Autoimmune nature

Pemphigus Foliaceus is an autoimmune disease, meaning the body's immune system mistakenly attacks healthy tissues. In this condition, specific antibodies, such as immunoglobulin G (IgG), target desmoglein-1 (Dsg1), a crucial protein involved in maintaining skin cell adhesion.^1,2 This immune system dysfunction results in the disruption of cell-to-cell connections in the epidermis, leading to blister formation and skin lesions.

Genetic predisposition

Genetics play a significant role in predisposing certain populations to Pemphigus Foliaceus. However, the exact genetic mechanisms are not entirely understood. Studies suggest a higher prevalence of the disease in specific ethnic groups. 

• Individuals of Jewish (especially Ashkenazi), Indian, Southeast European, Middle Eastern, or Brazilian descent, particularly in rural regions, exhibit increased susceptibility to pemphigus variants, including Pemphigus Foliaceus. 
• Certain variants in immune system genes known as HLA (human leukocyte antigen) have been linked to a higher risk of both Pemphigus Vulgaris and Pemphigus Foliaceus.⁵

Environmental triggers

Geographic location and environmental factors also contribute to the risk of developing Pemphigus Foliaceus. While Pemphigus Vulgaris is more widespread globally, Pemphigus Foliaceus is more prevalent in specific regions, such as rural areas of Brazil and Tunisia. These geographical variations suggest potential environmental triggers that might interact with genetic predispositions to precipitate the disease. 

Certain medications, including specific antibiotics, blood pressure medications, and drugs containing a chemical group called a thiol have been implicated in rare cases as triggers for Pemphigus.³

Symptoms and clinical presentation

Skin lesions

Pemphigus Foliaceus typically presents with a history of blister formation on the skin. These lesions predominantly begin on the trunk but can also manifest on the face or scalp. Due to their fragile nature, the blisters rupture easily, often leaving superficial sores or areas of crusting. Patients might report experiencing pain or a burning sensation in the areas of these lesions.

Unlike Pemphigus Vulgaris, Pemphigus Foliaceus generally lacks the presence of oral or other mucosal lesions. 

• Primary lesions observed are flaccid, superficial vesicles, and bullae on the skin, which may not always be visible during the examination due to their transient and fragile nature.
• Secondary lesions, such as shallow erosions, are more commonly observed. 

Scaling of these lesions is frequently seen, representing the detachment of the overlying skin layers.⁶

Common areas affected

The distribution of lesions in Pemphigus Foliaceus commonly involves the chest, back, shoulders, face, and scalp. On sun-exposed areas of the face, scalp, upper chest, and back lesions may develop, resembling the distribution pattern seen in lupus erythematosus (LE).⁷ Exudate from erosive lesions on the face and scalp often dries quickly, leading to the formation of crusts over an erythematous base.

Nikolsky’s sign in pemphigus foliaceus

• A pivotal clinical indicator in the diagnosis of Pemphigus Foliaceus is the presence of Nikolsky’s sign, a dermatological manoeuvre utilized to assess the skin's fragility and its susceptibility to separation within the epidermis. 
• When performing Nikolsky’s sign, clinicians apply gentle shear stress to the affected skin by rubbing the periphery of existing primary or secondary lesions, typically utilizing tangentially applied force.⁸

In the presence of Pemphigus Foliaceus, a positive Nikolsky’s sign manifests as the separation of the upper epidermal layers from the underlying lower layers when subjected to this shear stress. This separation, known as acantholysis, results in the detachment of skin layers, leading to blister formation or the development of shallow erosions.⁹

Fluctuating disease course

Pemphigus Foliaceus can exhibit a variable disease course. In its mildest form, patients might report solitary recurrent scaly and crusty lesions on the face, which might delay accurate diagnosis for years. Conversely, the disease can manifest in its severe form, resulting in exfoliative erythroderma characterized by widespread erythema and diffuse scaling of the skin. Severe cases may also lead to alopecia, necessitating immediate hospitalization to prevent potentially fatal complications from metabolic instability.

The variant Paraneoplastic Pemphigus (PE), combining features of Pemphigus Foliaceus and lupus erythematosus, presents with characteristic lesions, including flaccid vesicles and bullae in a butterfly distribution on the face, along with lesions on sun-exposed areas, often accompanied by positive antinuclear antibodies in serum.⁶

Diagnosis

Physical examination

The diagnosis of Pemphigus Foliaceus involves a comprehensive evaluation that begins with a detailed patient history and a thorough physical examination. Clinicians gather information about the patient's symptoms, including any history of blister formation, lesion distribution, pain, or burning sensations associated with the affected areas. The absence of mucosal involvement is a notable characteristic distinguishing Pemphigus Foliaceus from other variants.

Skin biopsy

Histology and direct immunofluorescence (DIF)

To confirm the diagnosis, tissue samples are obtained through a skin biopsy. For direct immunofluorescence (DIF) studies, the biopsy specimen is ideally taken from perilesional skin, which is the normal-appearing skin immediately adjacent to a lesion. This approach minimizes the risk of obtaining a false-negative result caused by the destruction of immune deposits in inflamed or blistered skin.¹⁰

Laboratory tests

Indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA)

Diagnostic studies such as indirect immunofluorescence (IIF) and ELISA require patient serum samples. These tests aim to detect the presence of autoantibodies in the patient's serum. Indirect immunofluorescence (IIF) helps in detecting circulating antibodies against components of the skin, while ELISA aids in quantifying specific autoantibodies.⁶

Diagnosis Criteria

• Overall Clinical Picture: This includes patient history, physical examination findings, and lesion distribution.
• Histopathological Findings: Examination of the skin biopsy specimen reveals specific characteristics under the microscope, confirming the presence of acantholysis or separation between skin layers.
• Presence of Autoantibodies: Immunofluorescent studies, both direct and indirect, help detect the presence of autoantibodies targeting skin components.

Treatment options

Medications

Corticosteroids

Corticosteroids, such as prednisone or prednisolone, represent the primary treatment for Pemphigus Foliaceus. These medications help suppress the immune system's abnormal response, reducing inflammation and preventing blister formation. Initial doses are often high, gradually tapering down once the condition is controlled to minimize side effects.¹¹

Immunosuppressants

In cases where corticosteroids alone are insufficient or to reduce corticosteroid dosage, immunosuppressive drugs like azathioprine, mycophenolate mofetil, or methotrexate may be prescribed. These medications target the immune system, preventing the production of antibodies that attack the skin.

Biological therapies

Biological therapies, such as rituximab, target specific immune cells that are involved in the autoimmune response. They may be considered in refractory cases or as an alternative to traditional immunosuppressive agents.¹²

Supportive care

Wound Care

Proper wound care is crucial to prevent infection and aid in healing. It involves gentle cleansing of affected areas, applying topical antibiotics to prevent secondary infections, and using non-adherent dressings to protect the skin.

Pain Management

Pain associated with Pemphigus Foliaceus lesions can be managed using non-steroidal anti-inflammatory drugs (NSAIDs) or topical analgesics to alleviate discomfort and improve the patient's quality of life.

Potential side effects and complications

Corticosteroid side effects

Prolonged use of corticosteroids can lead to various side effects, including weight gain, high blood pressure, diabetes, osteoporosis, mood changes, and increased susceptibility to infections.

Immunosuppressant side effects

Immunosuppressants also carry risks, such as increased susceptibility to infections, liver and kidney toxicity, gastrointestinal issues, and bone marrow suppression.

Biological therapies' risks

Biological therapies might increase the risk of certain infections, infusion reactions, and, in some cases, rare severe adverse events affecting the heart, lungs, or nervous system.

Complications

Without adequate treatment, Pemphigus Foliaceus can lead to complications such as widespread skin infection, sepsis, and potentially life-threatening conditions like electrolyte imbalances due to extensive skin loss (exfoliative erythroderma).¹³

Prognosis and long-term outlook

The prognosis for individuals with Pemphigus Foliaceus can vary widely. Many patients experience periods of remission and significantly improved quality of life. The disease course can be unpredictable, with periods of relapse and flare-ups.

Long-term management and consistent follow-ups with healthcare providers are essential to monitor the disease's progression and adjust the treatment plans. Severe cases may require prolonged immunosuppressive therapy, potentially leading to complications associated with long-term medication use.¹⁴

Current research and advancements

Recent advancements in Pemphigus Foliaceus treatment have introduced rituximab, a chimeric anti-CD20 monoclonal antibody, as a groundbreaking therapeutic intervention.¹⁵ Rituximab's mechanism involves B-cell depletion, which demonstrated significant efficacy in improving patient outcomes. This has marked a paradigm shift in treatment strategies, offering improved disease control while potentially reducing the reliance on prolonged corticosteroid use and traditional immunosuppressants.

Ongoing research continues to explore the optimal utilization and potential combination therapies involving rituximab, aiming to further enhance its efficacy, minimize adverse effects, and improve long-term outcomes for individuals affected by this condition.¹⁵

Lifestyle and coping strategies

Living with Pemphigus Foliaceus can pose challenges, both physically and emotionally. Adopting a healthy lifestyle, such as maintaining a nutritious diet, practising stress management techniques, and prioritizing adequate rest, can positively impact overall well-being.

Seeking support from healthcare professionals, joining support groups, or connecting with others facing similar challenges can provide invaluable emotional support and practical advice. Additionally, staying informed about the condition, adhering to prescribed treatment plans, and actively participating in one's care are crucial for effective management.

Summary

In conclusion, Pemphigus Foliaceus, a rare autoimmune blistering disease, presents complexities in diagnosis and management. While advancements in research offer promising avenues for improved treatments, current therapies centre around immunosuppression, supportive care, and vigilant monitoring.

Understanding the multifaceted nature of Pemphigus Foliaceus, embracing evolving treatment modalities, and fostering a proactive approach to healthcare are pivotal in enhancing the long-term outlook for individuals affected by this condition. Continued research endeavours and support systems are vital in improving outcomes and elevating the quality of life for those living with Pemphigus Foliaceus.